Olivia was an inspirational and vocal advocate for medicinal cannabis. She knew the important role medicinal cannabis could play in the journey of a cancer patient and was passionate about increased patient access.
When MCIA launched, she was excited to see the industry come together to discuss these important issues to ensure all patients had access to medicinal cannabis.
Continue reading “MCIA are deeply saddened to hear of the passing of Dame Olivia Newton-John”Please join MCIA and industry colleagues for a fireside chat and networking function. Daniel Rooney (Insurance broker, Marsh) will be in conversation with Will Clarke (Underwriter, NewLine) to discuss Understanding Clinical Trials and Insurance Requirements. Will and Daniel will discuss the in’s and outs of clinical trials, where claims typically occur and how to make sure you have the right protection in place
Continue reading “MCIA Networking Event: Understanding Clinical Trials and Insurance Requirements”Medicinal Cannabis Industry Australia (MCIA) has released a roadmap that outlines opportunities for the sector and strategic levers that need to be addressed to enable the sector to capitalise on these opportunities.
Continue reading “MCIA releases roadmap to growth for the Australian medicinal cannabis industry”ACannabis is back in 2022. With the theme, ‘Bridging the gap: evidence, confidence, access‘, ACannabis will be held over two jam packed days, Tuesday 15th March to Wednesday 16th March, and is the one location to stay up to date with all facets of the medicinal cannabis industry.
Due to the ever changing landscape, ACannabis 2022 will be a virtual conference and exhibition with a wide range of networking opportunities available. It will be immersive, engaging and deliver an:
Please join us for the inaugural MCIA networking event to socialise, celebrate and contribute ideas for developing future networking events! Each occasion will include a speaker and presentation on a topic of interest to the industry.
Continue reading “MCIA Industry Networking Event: Insights into evolving medicinal cannabis export opportunities”Developed by MTPConnect in partnership with Deloitte Access Economics, MCIA was pleased to initiate consultation with MTPConnect to develop this evidence based report for the industry and we thank MTPConnect for their support and work in developing this resource.
Continue reading “How will the Australian medicinal cannabis industry evolve?”Medicinal Cannabis Industry Australia (MCIA) is pleased to partner with FreshLeaf for the third year running in the release of FreshLeaf’s latest comprehensive analysis of medicinal cannabis products, pricing and patients.
Continue reading “Industry report shows strong growth in Australian patient access to medicinal cannabis”
MCIA is excited to invite you to an exclusive webinar hosted by FreshLeaf Analytics and AJD Media to present the H2 2021 FreshLeaf Analytics Market Report.
This report will be the 7th major publication from FreshLeaf, who has been covering the Australian medical cannabis industry since 2017, and is the leading source of information, data and insight on the sector.
Continue reading “MCIA Exclusive Webinar – Latest FreshLeaf Analytics Report H2 2021”Registration is now open for the TGA ‘Meeting Your Obligations – Supplying medicinal cannabis in Australia’ Workshop. MCIA has worked with TGA to deliver this workshop to assist members and others in the industry understand their obligations and specifically assist to understand the requirements for S3 over-the-counter (OTC) product registration requirements.
Continue reading “Meeting Your Obligations – Supplying Medicinal Cannabis in Australia Workshop”Medicinal Cannabis Industry Australia (MCIA) welcomes the Therapeutic Goods Administration (TGA) announcement of its final decision regarding down-scheduling of low-dose CBD, including the significant change to the maximum dose which has been increased to 150mg/day.
MCIA had recommended changes to the interim decision, and in particular the low daily dose, to ensure that there is an effective pathway for S3 CBD products. A report commissioned by MCIA supported a higher dose based on safety and efficacy, and hence, ability to meet the evidentiary requirements for the proposed registration pathway. MCIA is pleased that TGA’s further consideration of this information, along with other public submissions, and the advice of the Joint Committee of the Advisory Committees for Medicines Scheduling and Chemicals Scheduling at its November 2020 meeting, has led to a lifting of the daily dose.
Continue reading “MCIA welcomes decision for down scheduled CBD with increased maximum dose of 150mg/day”